AGC Biologics is expanding its CDMO services with plasmid DNA (pDNA) offerings from its Heidelberg site in Germany. The demand for pDNA is growing for many different applications such as the manufacturing of DNA adjuvants and vaccines and as a starting material for RNA drugs and cell-free protein expression platforms. In recent years, pDNA has been key for gene therapy applications for the creation of Lentivirus and Adeno-associated viruses as well as direct gene therapy.   “Our priority...